| Primary |
| Chronic Hepatitis C |
51.9% |
| Hepatitis C |
43.2% |
| Concomitant Disease Progression |
1.1% |
| Prophylaxis |
0.9% |
| Adverse Reaction |
0.8% |
| Hyperuricaemia |
0.5% |
| Constipation |
0.3% |
| Erythema |
0.3% |
| Infection |
0.3% |
| Adverse Event |
0.1% |
| Blood Uric Acid Increased |
0.1% |
| Peripheral Arterial Occlusive Disease |
0.1% |
| Pyrexia |
0.1% |
| Skin Disorder |
0.1% |
| Viith Nerve Paralysis |
0.1% |
|
| Rash |
22.6% |
| Drug Eruption |
8.4% |
| White Blood Cell Count Decreased |
7.9% |
| Hyperuricaemia |
6.8% |
| Haemoglobin Decreased |
6.3% |
| Renal Impairment |
6.3% |
| Neutrophil Count Decreased |
5.3% |
| Toxic Skin Eruption |
4.7% |
| Anaemia |
4.2% |
| Erythema Multiforme |
4.2% |
| Retinopathy |
3.2% |
| Renal Disorder |
2.6% |
| Retinal Haemorrhage |
2.6% |
| Erythema |
2.1% |
| Loss Of Consciousness |
2.1% |
| Pancreatitis Acute |
2.1% |
| Pneumonia |
2.1% |
| Pruritus |
2.1% |
| Pyrexia |
2.1% |
| Renal Failure Acute |
2.1% |
|
| Secondary |
| Chronic Hepatitis C |
31.9% |
| Hepatitis C |
23.7% |
| Prophylaxis |
17.3% |
| Hypertension |
6.8% |
| Hyperlipidaemia |
2.6% |
| Diabetes Mellitus |
2.3% |
| Product Used For Unknown Indication |
2.3% |
| Insomnia |
2.0% |
| Hyperuricaemia |
1.7% |
| Constipation |
1.4% |
| Iron Deficiency Anaemia |
1.2% |
| Rash |
1.1% |
| Gastrooesophageal Reflux Disease |
1.0% |
| Gastritis |
0.9% |
| Pyrexia |
0.9% |
| Gastric Ulcer |
0.8% |
| Nausea |
0.6% |
| Adverse Event |
0.5% |
| Depression |
0.4% |
| Eczema |
0.4% |
|
| Anaemia |
15.4% |
| Rash |
12.2% |
| Renal Impairment |
9.6% |
| White Blood Cell Count Decreased |
7.4% |
| Haemoglobin Decreased |
5.8% |
| Drug Eruption |
5.3% |
| Decreased Appetite |
5.1% |
| Platelet Count Decreased |
5.1% |
| Renal Disorder |
5.0% |
| Vomiting |
4.1% |
| Malaise |
3.4% |
| Hyperuricaemia |
3.3% |
| Nausea |
2.7% |
| Retinopathy |
2.7% |
| Blood Creatinine Increased |
2.4% |
| Toxic Skin Eruption |
2.3% |
| Erythema Multiforme |
2.3% |
| Erythema |
2.1% |
| Pyrexia |
1.9% |
| Neutrophil Count Decreased |
1.8% |
|
| Concomitant |
| Hepatitis C |
50.6% |
| Prophylaxis |
20.2% |
| Hypertension |
11.2% |
| Gout |
4.5% |
| Hyperlipidaemia |
4.5% |
| Hyperuricaemia |
3.4% |
| Gastrooesophageal Reflux Disease |
2.2% |
| Iron Deficiency Anaemia |
2.2% |
| Chronic Hepatitis C |
1.1% |
|
| Anaemia |
46.7% |
| Tongue Disorder |
20.0% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
6.7% |
| Pruritus |
6.7% |
| Toxic Skin Eruption |
6.7% |
| Transfusion |
6.7% |
| Type 1 Diabetes Mellitus |
6.7% |
|
